Abstract
Background: Based on current guidelines, ticagrelor/prasugrel are preferred over clopidogrel in myocardial infarction (Ml) treated with percutaneous coronary intervention (PCI) and drug eluting stent (DES). In Malaysia, clopidogrel is still the most commonly used ADP antagonist. The role of routine platelet function testing (PFT) with point of care instruments (POC) has not been established.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
